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Human LRRK2 (Leucine-Rich Repeat Kinase 2) has been associated with both familial and idiopathic Parkinson’s disease (PD).
Although several LRRK2 mediated pathways and interaction partners have been identified, the cellular functions of LRRK2 and
LRRK2 mediated progression of PD are still only partially understood. LRRK2 belongs to the group of Roco proteins which
are characterized by the presence of a Ras-like G-domain (Roc), a C-terminal of Roc domain (COR), a kinase, and several
protein-protein interaction domains. Roco proteins exhibit a complex activation mechanism involving intramolecular signaling,
dimerization, and substrate/effector binding. Importantly, PD mutations in LRRK2 have been linked to a decreased GTPase and
impaired kinase activity, thus providing putative therapeutic targets. To fully explore these potential targets it will be crucial to
understand the function and identify the pathways responsible for LRRK2-linked PD. Here, we review the recent progress in
elucidating the complex LRRK2 activation mechanism, describe the accumulating evidence that link LRRK2-mediated PD to
mitochondrial dysfunction and aberrant autophagy, and discuss possible ways for therapeutically targeting LRRK2.
1. Introduction
Parkinson’s disease (PD) is a progressive motor disorder that
is caused by the degeneration of dopaminergic neurons in
the midbrain. The prevalence of PD increases with age, with
2% of individuals over the age of 80 being affected thereby
representing the second most common neurodegenerative
disorder worldwide [1–3]. Causations are various and mostly
divided into a sporadic form without a clear trigger and a
familial form inwhich a genetic factor is involved.Themono-
genic form of PD is caused by a single mutation in a reces-
sively or dominantly inherited gene. It has been found in
sporadic as well as familial PD and accounts for approx-
imately 3–5% and 30% of the cases, respectively [4, 5].
Mutations in SCNAandLRRK2 (Leucine-RichRepeatKinase
2) are a specific subset of familial PD as they are autosomal-
dominant with LRRK2 representing the most common cause
of inherited PD [5]. It belongs to the Roco family of proteins,
which constitutes a novel family of Ras-like G-proteins being
conserved in almost all kingdoms of life [6–8].
LRRK2 is a large (286 kDa) and complex protein with a
uniquemultiple-domain architecture (Figure 1), consisting of
Armadillo repeats (ARM), Ankyrin repeats (ANK), leucine-
rich repeats (LRR), a Ras of complex proteins (Roc), a C-
terminal of Roc (COR), a kinase domain, and WD40 repeats
[2, 6, 7].
Over 40 LRRK2 mutations have been identified repre-
senting risk factors for PD [9–11]. Most of the verified patho-
genic PD-linked LRRK2 mutations are accumulated around
the central core of the protein; one is found in the LRR,
one in the Roc domain (with multiple substitutions), one in
the COR domain, and two in the kinase domain (Figure 1).
The multiple disease-linked mutations in LRRK2 represent
a unique opportunity to explore the activation mechanism
of the protein, its misregulation in PD, and the underlying
molecular mechanisms of genetic and sporadic PD.
In this review, we will focus on the recent progress in
elucidating the complex LRRK2 activationmechanism, high-
light the evidence for a role of LRRK2 in the mitochondrial
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Figure 1: Schematic diagram of the domain architecture of LRRK2. Above, the segregating mutations of LRRK2 in Parkinson’s disease are
shown (arrows). ARM: Armadillo repeats, ANK: Ankyrin repeats, LRR: leucine-rich repeats, and WD: WD40 repeats.
and autophagy pathways, and discuss possible ways to thera-
peutically target LRRK2-mediated PD.
2. LRRK2 Kinase and GTPase Activity
LRRK2 has two bona fide enzymatic activities via its Roc
(GTPase) and kinase domain. Several studies have shown that
the Serine/Threonine specific kinase activity is responsible for
LRRK2-mediated PD symptoms, including the degeneration
of nigrostriatal dopaminergic neurons and the formation
of Lewy bodies [2, 4, 12–14]. While PD-mutated LRRK2
triggers increased inclusion body formation in SH-SY5Y and
cell death in primary rat cortical neurons, both of these
phenotypes were diminished upon introduction of a LRRK2
kinase dead mutation [15]. For a long time, the function of
the kinase domain has been considered as the main output
of LRRK2. However, only for the G2019S PD mutation,
representing the most common pathogenic point mutation,
an increased phosphorylation activity has been reported [16–
18]. For other pathogenic mutations, inconsistent, modest,
or no effect on kinase activity has been shown [16–18]. Fur-
thermore, PD mutations in LRRK2 probably have different
defects in its activation mechanism and it is unclear if all
pathogenic effects are mediated via the kinase domain [17–
19]. Also the enzymatic activity of the Roc domain is affected
in LRRK2-mediated PD-mutants and recent data strongly
suggest that PD mutations in both Roc and COR domains
result in decreased GTP hydrolysis [18, 20–24]. The Roc
domain of LRRK2 belongs to the family of small G-proteins
which are GTP binding proteins switching between an active
GTP- and inactive GDP-bound state (Figure 2) [25]. Studies
with both LRRK2 and an amoebic homologue revealed that
a functional Roc domain is essential for kinase activity and
disruption of Roc or the kinase domain by a single point
mutation leads to the complete inactivation of the protein
[15, 22, 23, 26]. In vivo studies with LRRK2 G2019S showed
that primary neurons possess a lower level of toxicity after
the GTPase function was abolished [27]. Further studies
confirmed thatGTPase activity is central for neuronal toxicity
and LRRK2 pathobiology in human cell lines and model
organisms [20–22]. However, the data prove the involvement
of both enzymatic activities in the onset of PD and imply a
present cross-talk between the two domains.
3. LRRK2 Activation Mechanism
The exact molecular mechanism by which the catalytic






















Figure 2: Proposed model of the activation mechanism of LRRK2.
LRRK2 activation is at least regulated by three differentmechanisms:
cycling between (1) an almost inactive monomer and active dimer
at the membrane, (2) intramolecular activation, and (3) binding of
input/substrate to the N- and C-terminal domains.
accumulating evidence suggests the involvement of at least
three differentmechanisms: dimerization in close association
with localization, intramolecular activation, and binding of
input/substrate to the N- and C-terminal domains (Figures 2
and 3).
LRRK2 is monomeric and almost inactive in the cytosol,
while it is predominantly dimeric and active when localized
at the membrane [28–32]. Membrane enriched LRRK2 dis-



































Figure 3: Proposed pathways regulating LRRK2-mediated mitochondrial homeostasis and autophagy.
higher kinase activity in comparison to the cytosolic LRRK2
suggesting that localization is dependent on and affects
phosphorylation [31, 33, 34]. Structural studies with bacterial
Roco proteins have revealed that the COR domain functions
as an essential dimerization device [35]. During dimerization,
the catalytic machinery for the GTPase reaction is being
formed by complementation of the active site of one protomer
with the other protomer [33, 35]. COR truncated proteins
that are not able to dimerize have a drastically lower (700
times) GTPase activity. Interestingly, abolishing dimerization
also alters autophosphorylation levels, indicating that both
enzymatic activities are critically dependent on dimerization
[35–38]. In this way, the intramolecular GTPase reaction
functions as a timing device for the activation and biological
functions of Roco proteins. Interestingly, a recent study has
shown that mutations of known phosphorylation sides in
the G-domain affect both kinase and GTPase activity [30].
Together the data suggest that the Roc-COR tandem is reg-
ulating kinase activity, the kinase is regulating the GTPase
activity of Roc, and both events are critically involved in
LRRK2 cellular distribution.
LRRK2 dimerization and activation is regulated by theN-
and C-terminal LRRK2 protein-protein interaction domains.
Cellular studies with LRRK2 and related Roco proteins lack-
ing theN- orC-terminus suggested their essential role for sig-
naling in vivo [7, 39].
Deletion of the WD40 repeats led to impaired dimer
formation accompanied with diminished kinase activity and
aberrant protein localization [40]. Recent data suggest that
the N-terminus inhibits LRRK2 kinase activity, since deletion
of the terminus resulted in increased LRRK2 autophosphory-
lation levels when expressed in human cell lines [32]. On the
contrary, LRRK2 G2019S PD mutation displayed increased
kinase activity with a lower level of autophosphorylation of
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the N-terminus (S910/935∼P) [32, 41]. Although the N- and
C-terminus of LRRK2 have an essential role in vivo, they
are not required for kinase activity in vitro [7, 39]. This
might suggest that the N- and C-terminal protein-protein
interaction domains regulate LRRK2 activity by binding to
upstream and/or downstream effectors. In this perspective,
it has been shown that the N-terminal segment of LRRK2
interacts in a phosphorylation dependent manner with the
ubiquitous regulatory protein 14-3-3. Disruption of the phos-
phorylation sides S910 and S935 blocks 14-3-3 binding and
leads to the delocalization of LRRK2 from themembrane and
its accumulation in the cytosol (Figure 3) [34, 41]. Recently,
members of the Rab family of small GTPases have been
identified as valid LRRK2 interactors and substrates [42–44].
In vivo studies confirmed direct binding, most likely medi-
ated via the N-terminus, and colocalization of LRRK2 with
Rab5 and Rab7, suggesting an involvement in degradative
and endocytic membrane trafficking (Figure 3). Strikingly,
the PD mutation G2019S disrupted molecular trafficking
and colocalization with Rab7, resulting in the formation of
aberrant endosomal structures and endosomal/lysosomal
localization thus interferingwith the cellular degradative traf-
ficking pathway of organelles [45, 46]. Furthermore, LRRK2
binding to Rab32 is regulating its localization to lysosomes as
well as mitochondria [47].
4. LRRK2-Mediated Mitochondrial
Dysfunction, Autophagy, and Cell Death
Numerous potential LRRK2 mediated pathways have been
identified; however, much about its cellular functions and
LRRK2 mediated progression of PD remains unknown.
Accumulating evidence links LRRK2-mediated PD to mito-
chondrial dysfunction and aberrant autophagy (Figure 3)
[48–51]. LRRK2 transfected HEK-293T cells showed a 10%
enhanced localization of LRRK2 to the outer but not inner
mitochondrial membrane [51]. The morphology and inter-
connectivity of mitochondria in skin samples of G2019S car-
rier patients were detected to be abnormal, most likely due
to dysregulated fission and fusion events [50]. Analysis of
the substantia nigra of patients with idiopathic PD revealed
a glutathione depletion and mitochondrial complex-I defi-
ciency, both representing known indicators of oxidative stress
[52]. Furthermore, polymorphism inmtDNA (mitochondrial
DNA) and aberrant levels of the neurotoxinMPP+ (1-methyl-
4-phenylpyridinium) and its precursor MPTP (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) were found in patient
samples, various model organisms, and human culture cell
lines [53]. In neurons it was shown that LRRK2 colocalizes
with the Dynamin like protein 1 (DLP1), a known mitochon-
drial fission factor (Figure 3). Expression of LRRK2 G2019S
and R1441C in neurons induced mitochondrial fragmenta-
tion and increased their interaction ratewithDLP1which also
displayed higher phosphorylation levels, resulting, among
others, in an enhanced level of reactive oxygen species (ROS).
All these defects could be rescued by silencing of DLP1,
suggesting a LRRK2/DLP1 pathway regulatingmitochondrial
fission events and their clearance [51, 54]. Localization of
LRRK2 is not limited to mitochondrial structures but was
found at a variety of additional membranes, including mul-
tivesicular bodies (MVBs) representing autophagic vacuoles
(AVs) [55]. Consistently, being involved in the regulation
of the endosomal-autophagic pathway, expression of PD-
mutated LRRK2 triggered the accumulation of (abnormal)
MVBs and AVs via misbalancing the induction of macroau-
tophagy and maturation of AVs to lysosomes (Figure 3) [55].
Furthermore, expression of LRRK2 G2019S in human cell
lines led to the shortening of neurite length and an increase
in autophagic vacuole levels [15, 56].
The pathways regulating and linking LRRK2 PD-medi-
ated mitochondrial dysregulation and abnormal autophagy
are only partly identified but most likely include the activa-
tion of the autophagy regulating protein 5󸀠 AMP-activated
protein kinase (AMPK) [45, 57].The abnormal kinase activity
of LRRK2 G2019S in human cell lines leads to an increased
level of phosphorylated AMPK, which subsequently results
in enhanced levels of autophagosomes [58]. The mitogen-
activated protein kinases (MAPK) cascade may represent
another important pathway regulating LRRK2-mediated
autophagy. In addition to enhanced autophagic activity and
cell death, cells expressing LRRK2 G2019S also showed a
threefold increase in protein turnover and a higher level
of phosphorylated MAPK/ERK. Incubation with a specific
inhibitor ofMEK1/2 (U0126)was sufficient to rescue the aber-
rant phenotypes of the LRRK2 G2019S cells [56, 59]. It was
suggested that LRRK2 induces autophagy via the activation
of NAADP (nicotinic acid adenine dinucleotide phosphate)
receptors, which are involved in the calcium efflux from
endosomes [58]. The mitochondrial antiapoptotic protein,
Bcl-2, might represent the connection between LRRK2-
induced dysregulated mitochondrial homeostasis and auto-
phagy. Expression of phosphorylated Bcl-2 rescues both the
mitochondrial and autophagy defects of LRRK2 G2019S cells
[60].
Several other PD associated proteins, including 𝛼-
synuclein, Parkin, DJ-1, PINK1, and HtrA2, have been linked
to similar defects in mitochondria regulation and autophagy
[37, 61, 62]. Parkin, a known regulator of mitochondrial
clearance, and AMPK seem to be directly involved in an
alternative or parallel pathway as overexpression acted pro-
tectively against cellular toxicity in fly dopaminergic neu-
rons expressing mutated LRRK2 [61]. Mutations in Parkin
and PINK1 (PTEN-induced kinase 1), both mitochondria
regulating proteins, have been found in sporadic as well as
autosomal recessive PD and result in severe mitochondrial
abnormalities and cell death [63]. The parallel expression
of PD-LRRK2 in PINK1 and DJ-1 deficient fly cells or
mice neurons with abnormal 𝛼-synuclein activity leads to
an increase of respective pathogenic phenotypes [64, 65].
Deletion of LRRK2 acts in a neuroprotective way towards
𝛼-synuclein mediated effects in mouse models [65]. DJ-1 is
only partially able to rescue the phenotypes of PINK1mutated
neurons but, vice versa, overexpression of both Parkin and
PINK1 restores the abnormal mitochondrial morphologies of
DJ-1 deficient cells, suggesting a present connection between
the involved pathways [66, 67]. Altogether it might suggest
the presence of common PD-pathogenic pathways that result
in mitochondrial dysfunction and autophagy.
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5. Therapeutic Targeting of LRRK2
Themajor focus of academia and industry is the development
of kinase inhibitors as potential therapeutics for LRRK2-
mediated PD.Almost all clinical kinase inhibitors are used for
short-time treatment in the cancer field and for immunologi-
cal, neurological, and infectious diseases, where side effects
caused by high dosage are tolerated [68]. In contrast, for
the long-term treatment of chronic diseases such as LRRK2-
associated PD no potential toxic side effects can be present.
Several highly specific and brain penetrant LRRK2 kinase
inhibitors were identified but have yet to be optimized in
order to qualify as drug candidates for therapeutic treatment
[69–72]. Our structures of a humanizedD. discoideum Roco4
kinase domain bound to the common inhibitors LRRK2-
IN-1 or Compound 19 revealed a highly similar binding
mechanism and gave important information for potential
optimization [73]. However, accumulation in peripheral tis-
sues, especially kidneys and lungs, and related drug induced
toxicity are still a major and common problem for all LRRK2
kinase inhibitors [72, 74, 75]. In rodent models, enhanced
dosages of the recent highly specific and brain penetrant
LRRK2 kinase inhibitors GNE-7915 and GNE-0877 are well
tolerated over a longer time period; however, they induced
the cytoplasmic accumulation of lysosome-related organelles
in the lungs of nonhuman primates [76].
Understanding how other domains of LRRK2 modulate
its activity is an important but rather neglected field in LRRK2
research and not a focus of industries. However, the PD
causing mutations are found in nearly all domains of LRRK2
leading to the same well described symptoms. Furthermore,
as recent data suggest that different PD mutations have
diverse defects with regard to the activationmechanism, they
might require specified ways of inhibition for the purpose of
drug development [72, 74, 77].
Alternative approaches targeting further LRRK2 domains
and sites of its complex activation mechanism, including the
N- and C-terminus, the catalytic GTPase activity of Roc,
LRRK2 localization, dimerization, or allostericmodulation of
the kinase domain, might significantly improve therapeutic
benefits (Figure 2).
The LRRK2 mutations in the Roc (R1441C/G/H) and
COR (Y1699C) domain have a decreased GTPase activity
and a functional LRRK2 G-domain is essential for LRRK2
activation, suggesting GTPase activity forms an interesting
therapeutic target [20, 78–80]. Targeting the G-domain could
be done by using small compounds that bind and interfere
with nucleotide binding, resemble the GDP-bound off-state,
or increase the GTPase cycle. Recently, the first LRRK2 GTP
binding inhibitors, compounds 68 and 70, were identified and
proved to inhibit both GTPase and kinase activity in vitro as
well as in vivo and thereby attenuated neuronal degeneration
in human cell lines/rodent tissues [14]. Importantly, FX2149, a
novel analog of 68, even displayed an around two times higher
brain inhibition efficiency in a rodent model organism [81].
The N- and C-terminal segments of LRRK2 contain sev-
eral protein-protein interaction domains which are involved
in regulating kinase activity, oligomerization, and/or local-
ization. As described above, LRRK2 cycles between a low
active monomeric cytosolic state and a high active dimeric
membrane bound state. Importantly, since LRRK2 activation
is dependent on membrane localization and dimerization,
inhibiting either of these properties may be a good therapeu-
tic approach.
6. Summary
Recent studies have shed light on the complex activation
mechanism of LRRK2 and revealed highly precise and exact
timed interactions on both intra- and intermolecular levels.
These multiple layers of regulation and enzyme activities
within one protein make LRRK2 an interesting therapeutic
target. To further explore these therapeutic targets, it will be
essential to completely characterize the molecular activation
mechanism. Biochemical and structural characterization of
LRRK2 and/or related Roco proteins can give important
information about the dimerization mechanism, how the
kinase domain regulates GTPase activity, howLRRK2 activity
is regulated by binding of input or substrate to the LRR
and WD40 domains, and how the PD mutations influence
the complex regulatory mechanism. Recent data strongly
suggest that LRRK2 dysfunction in PD results in mitochon-
drial defects and autophagy. However, the precise underlying
mechanisms are still not well understood andmany questions
about the cellular function of LRRK2 remain to be addressed,
including at which (inter)cellular membrane LRRK2 is acti-
vated and if common underlying pathways of familial PD
are existing. To answer these questions, it will be crucial to
identify physiological kinase substrate(s) and upstream and
downstream regulators.
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